Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study
No Thumbnail Available
Date
2024
Journal Title
Journal ISSN
Volume Title
Publisher
Dove Medical Press Ltd
Abstract
Purpose: Diabetes is a public health problem that requires strategies to impact glycemic control and reduce the risk of long-term medical complications. Pharmacological management is a necessary treatment for this disease. Therefore, semaglutide is an essential tool to achieve the treatment targets. The present study aimed to evaluate the semaglutide effects on a cohort with type 2 diabetes mellitus (T2DM) in Colombia. Materials and Methods: The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6-and 12-month follow-up. Results: Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD −2.74 CI −1.95 to −3.52 in 6 months), fasting plasma glucose levels, body weight (MD −7.11 CI −5.97 to −8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events. Conclusion: This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM.
Description
Keywords
diabetes mellitus, glycated hemoglobin A, glycemic control, obesity, semaglutide
Citation
Balcázar-Valencia, C. M., García-Ramos, A. F., Osorio-Toro, L. M., Ordoñez-Guzmán, Y. A., Buitrago-Gómez, N., Cabarcas-López, W. F., Vizcaino-Guerrero, C. J., Daza-Arana, J. E., Ramírez-Rincón, A., & Restrepo-Erazo, K. (2024). Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study. Diabetes, Metabolic Syndrome and Obesity , 17, 1667–1673. https://doi.org/10.2147/DMSO.S443115